Forgot your password?

Forgot your username?

Amarantus BioScience Holdings, Inc. Biotech Specialty Pharma

655 Montgomery Street, Suite 900
San Francisco, CA 94107 USA
Click for website
Research Sector Biotech Specialty Pharma
Summary Description Biotechnology company that develops modifying treatments to address cell death.

Click here for Financial Data KeywordsParkinsons Disease, PD, CNS, cell death, biotechnology, apoptosis, neurodegenerative diseases, cardiovascular diseases, cardiovascular, neurodegenerative, Parkinsons disease, Myocardial Infaraction, brain health


Amarantus Biosciences Pioneering the development of a novel therapeutic protein that has neuron-protective properties - termed MANF - which has the potential to serve as a first-in-class treatment for......view more

Products / Services

The most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinsons Disease and Myocardial Infarction. Parkinsons Disease generates over $2B in sales annually, and ......view more

Technology / Differentiation

Discovered from Amarantus proprietary Discovery Engine for Secreted Proteins (DESP), AMRS001, also known as MANF, is a highly potent, neurotrophic factor currently in pre-clinical development for the ...view more

Market / Customers

5.2 MM Americans with Alzheimer's Disease; 200k under 65 with younger-onset Alzheimer’s. By 2025, the number of people with Alzheimer’s expected to reach 7.1 MM. At least 500k people with PD and ~50......view more

Competitors / Substitutes / Alternatives

There are two broad categories of diagnostics for AD and PD being pursued – genetic and molecular (proteins/biomarkers). Both diagnostics utilize patient material obtained from tissue, blood, urine, ...view more


Amarantus business strategy, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine...view more